GlassScriptPhysician profile
Ashley Stines
NPI 1497373328
$29,090.48
in general payments reported to CMS, 2019-2025
16 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $1,142 · 2023: $4,182 · 2024: $9,580 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $6,610 · Food and Beverage: $5,408 · Consulting Fee: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,245.00 |
| Travel and Lodging | $6,610.13 |
| Food and Beverage | $5,408.06 |
| Consulting Fee | $1,570.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25,525.54 | 2022-2025 | Biktarvy |
| Viiv Healthcare Company | $2,399.66 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $234.95 | 2022-2023 | Symtuza |
| Janssen Products, LP | $222.10 | 2022-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $169.19 | 2022-2025 | Pifeltro, Delstrigo, Enflonsia |
| Abbvie INC. | $125.92 | 2021-2023 | |
| Lilly USA, LLC | $101.31 | 2023 | Mounjaro |
| Janssen Scientific Affairs, LLC | $63.35 | 2022 | |
| Novo Nordisk INC | $55.67 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $34.88 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $34.41 | 2024 | |
| Shield Therapeutics INC | $34.09 | 2025 | |
| Corcept Therapeutics | $31.75 | 2021-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Glaxosmithkline, LLC. | $15.51 | 2024 | Bexsero |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $13.67 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Stines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.